State of the evidence: Overall assessment: human evidence is limited and varies by outcome. Mechanisms, biomarkers and clinical benefit should not be treated as interchangeable.
Prostate follow-up: PSA dynamics
Single-arm prostate research has focused on PSA patterns after previous local treatment.[1] The question concerns how a monitoring marker changes during the study period. Readers should separate that question from whether tumors shrink or people live longer. On an evidence map, these findings belong under biomarker research, rather than under direct demonstrations of improved survival or prevention of cancer spread.
Cardiovascular research: Intermediate measures
The hypertension trial compared collagen markers and cardiovascular measurements without demonstrating significant superiority for MCP.[2] This domain illustrates how indicators of tissue processes enter clinical research. Whether a person is hospitalized or experiences a heart attack represents a different endpoint. Although the outcomes concern the same broad system, they should not be substituted for one another or treated as interchangeable evidence.
Knee osteoarthritis: Symptoms and function
The knee osteoarthritis study assessed symptoms and disease burden without finding an advantage over placebo.[3] Here, reports about pain and everyday function are central. Unlike a laboratory value, they address lived experience. Changes in the intervention group still need comparison with the control group. The fact that an outcome concerns symptoms does not remove the need for a design capable of supporting the conclusion.
Advanced tumors: Quality of life and composite benefit
A pilot involving different advanced solid tumors investigated clinical-benefit and quality-of-life outcomes.[4] Deriving an expectation for one particular cancer from such a group is difficult. A composite outcome may also gather changes in different domains under one heading. Mapping this evidence requires attention to the components measured, the participants completing assessment and the presence or absence of an appropriate comparison.
Why these domains cannot become one score
PSA patterns, vascular measurements, knee pain and quality of life do not share a single scale. Pooling participants across unrelated questions to calculate a general success percentage confuses the outcomes. A separate statement for each domain is more informative: who was studied, what was measured and how certain is the conclusion? This preserves favorable and unfavorable observations within the context that gives them meaning.
Reading the spaces left on the map
Research in one health domain does not answer every proposed use within it. Longer observation, different populations or everyday outcomes may require their own evidence. When reading the next paper, first identify which question on this map gains information. Is it a mechanistic explanation, continued observation of the same participants or an independent clinical comparison? That distinction clarifies how the evidence is developing without inflating what has been established.
References
- Keizman et al., 2021 — Prostate PSA study
- Lau et al., 2021 — Cardiovascular measurements in hypertension
- Andrews et al., 2020 — Knee osteoarthritis outcomes
- Azémar et al., 2007 — Clinical benefit in advanced solid tumors
This article provides general health information. Research findings about MCP are not individual recommendations for diagnosing or treating disease. Medicine and supplement use should be discussed with a doctor or pharmacist.
Published and sources assessed: 17 October 2026